BioCentury | Sep 22, 2020

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

With its €380 million takeout of Dublin-based Inflazome, Roche is continuing the rush of pharmas targeting inflammasome companies in a deal that leaves NodThera as the last company standing among the first crop of high...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Promoting expression of immune targets IFI16 and NLRC5 for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Promoting the expression of immune genes IFI16 and NLRC5 directly, or indirectly by inhibiting epigenetic protein PRMT5, could treat melanoma. In patients, high tumor expression of IFI16 or NLRC5 and...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

Ventus emerged from stealth on Wednesday with a Versant-led $60 million series A round and a drug discovery platform designed to tackle one of the biggest challenges of targeting innate immune signaling: the lack of...
BioCentury | Feb 18, 2020
Politics, Policy & Law

Sharpless' homecoming: the NCI chief's lessons from his time at FDA

NCI Director Ned Sharpless has returned from his seven month stint as acting FDA Commissioner aiming to take on the regulatory hurdles that lie ahead for promising technologies, and seeking ways for NCI's grants to...
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

...suggests NLRP1 and NLRP2 are tied to autoimmunity and fibrosis; NLRP12 is involved in arthritis; NOD2...
...domain containing 7 NLRP12 (NALP12) - NLR family pyrin domain containing 12 NOD2 (CARD15) - Caspase recruitment domain family member 15...
BioCentury | Jun 29, 2019

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
BioCentury | Apr 12, 2019
Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
BioCentury | Apr 6, 2019

Big caps under pressure

...II ACHIEVE trial of Inarigivir soproxil, a small molecule nucleic acid hybrid targeting RIG-I and NOD2...
...Stem cell factor receptor tyrosine kinase ICOS - Inducible T cell co-stimulator NOD2 (CARD15) - Caspase recruitment domain family member 15...
BioCentury | Jan 18, 2019
Clinical News

FDA panel backs Amgen's Evenity for osteoporosis

FDA's Bone, Reproductive and Urologic Drugs Advisory Committee voted 18-1 in favor of Evenity romosozumab from Amgen Inc. (NASDAQ:AMGN) and UCB S.A. (Euronext:UCB) to treat osteoporosis in postmenopausal women at high risk of fracture. Amgen...
Items per page:
1 - 10 of 147